If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
2 September 2020 Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
9 April 2020 A California federal judge has issued a final award of $1.2 billion in damages to Bristol-Myers Squibb subsidiary Juno Therapeutics in its patent infringement dispute with Gilead’s Kite Pharma.
2 September 2020 Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
9 April 2020 A California federal judge has issued a final award of $1.2 billion in damages to Bristol-Myers Squibb subsidiary Juno Therapeutics in its patent infringement dispute with Gilead’s Kite Pharma.
2 September 2020 Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
9 April 2020 A California federal judge has issued a final award of $1.2 billion in damages to Bristol-Myers Squibb subsidiary Juno Therapeutics in its patent infringement dispute with Gilead’s Kite Pharma.
